Cardiac MRI for Differential Diagnosis of Non-ischemic Heart Disease

Non-ischemic heart disease (NIHD) may have different etiologies and is often the cause of heart failure, with reduced or preserved cardiac function. An estimated 64.3 million people are living with heart failure worldwide1 and its impact is increasing in an ageing society. Hence the etiology of the disease is particularly relevant for therapeutic decision-making in any ever-growing number of patients. Cardiac MRI (CMR) is the only non-invasive imaging modality which is able to differentiate between underlying diseases and can, in case of NIHD, act like a virtual biopsy.

The following articles illustrate the utilization of CMR in patients with various types of NIHD.  

1 Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020 Aug;22(8):1342-1356.


Chiara Bucciarelli-Ducci, MD, PhD, FESC, FRCP, AFCC, FSCMR, FEACVI
(Royal Brompton and Harefield Hospitals, London, UK)

Professor Bucciarelli-Ducci takes a look at

  • the role of CMR in the guidelines
  • benefits of CMR in ischemic heart disease
  • benefit of CMR in non-ischemic cardiomyopathies
The Masterclass ends with an interactive case reading.


Jeanette Schulz-Menger, M.D.; et al. (Charité and HELIOS Hospital Berlin-Buch, Germany)

The complexities of diagnosing MINOCA and INOCA remain challenging. Chiara Bucciarelli-Ducci, MD and Colin Berry, MD will talk in the following webcast about the potential of MR imaging for risk assessment and prognosis in MINOCA and INOCA patients.

case study preview

Robert Sykes, Colin Berry, et al.
(West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow, UK & Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK)

SCMR edition MAGNETOM Flash

Download complete edition

Download editorial comment by Guest Editor Gemma A. Figtree (University of Sydney and Royal North Shore Hospital, Sydney, Australia)

This SCMR edition of MAGNETOM Flash provides an overview regarding the emerging role of CMR with more stratified approaches to common clinical cardiology challenges. Better stratification by underlying mechanistic markers – both imaging and blood based – will be the central ingredients to making the next advances in prevention, early detection and treatment of many cardiovascular conditions. CMR and the non-invasive window that it provides into myocardial pathology, without the need for myocardial biopsy, will undoubtedly be a central player in both better diagnosis management of individual patients as well as advances in the field through coordinated stratification and targeting of novel therapies in more efficient and powerful trials.